HCW Biologics Inc. reports today with one of the most aggressively shorted lending setups in the small-cap biotech universe — a rare combination of sky-high short interest, near-maximum cost to borrow, and a lending pool that has run completely dry.
Short interest is the dominant story here. At 21.3% of the free float, the bearish position is substantial. More striking is the pace of accumulation: shorts nearly quadrupled over a single week, with shares short jumping roughly 290% in the five sessions through May 13. The ORTEX short score reflects this — it leapt from 63.6 to 75.8 between May 7 and May 11, one of the sharpest week-over-week moves visible in the recent history. That score now ranks in the 6th percentile of the universe, meaning HCWB carries more short pressure than 94% of comparable names.
The lending market reinforces how extreme the positioning has become. Borrow availability has collapsed to zero — every share in the lending pool is currently out on loan, matching the 52-week tightest level. Yet the cost to borrow, running at roughly 330% annualised, has barely budged over the past week, down just 3%. That combination — fully exhausted availability with stable borrow costs — points to a lending market that has priced in the squeeze risk but has no more room to accommodate fresh shorts. The days-to-cover reading of 1.0 is mechanically low given the thin float, but the borrow constraint is the binding one: new entrants simply cannot get access. The stock itself closed at $0.337 on May 14, down 3.5% on the day but up 5.2% on the week — a volatile, low-price profile that amplifies both directions.
The analyst picture offers little additional signal. The sole available price target — $2.00 from a consensus struck in early March — is stale at 71 days old, and the most recent individual note on record dates to May 2025, when Maxim Group maintained a Buy rating while cutting its target sharply. At a current price of $0.337, no reliance can be placed on published targets without risking a significant currency or listing mismatch. Insider buying data is similarly dated, with the last cluster of purchases recorded in February 2024 at $1.40 per share — well above current levels, and too old to carry meaningful signal for today's print. Institutional ownership is thin: the top holder, Hing Wong (the company's founder and CEO), held 6.7% of shares as of late April but trimmed the position by roughly 51,000 shares. Peer biotech names offered a mixed backdrop through the week, with AGIO gaining 6.6% and TPST falling 8.9%, underlining how idiosyncratic micro-cap biotech moves can be around catalysts.
Today's print will test whether the sharp build in short interest over the past week reflected informed positioning ahead of a negative catalyst — or an overcrowded trade now facing a dried-up borrow pool with no room to add pressure.
See the live data behind this article on ORTEX.
Open HCWB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
